Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) Director Dennis Matheis bought 245,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $1.00 per share, for a total transaction of $245,000.00. Following the completion of the transaction, the director directly owned 1,033,443 shares of the company’s stock, valued at $1,033,443. This trade represents a 31.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Lucid Diagnostics Trading Up 7.0%
NASDAQ:LUCD opened at $1.07 on Friday. The firm has a market capitalization of $217.28 million, a price-to-earnings ratio of -2.28 and a beta of 1.10. Lucid Diagnostics Inc. has a 1-year low of $0.90 and a 1-year high of $1.70. The business’s fifty day moving average price is $1.16 and its 200 day moving average price is $1.18.
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $1.38 million. Equities analysts forecast that Lucid Diagnostics Inc. will post -0.22 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Analysis on LUCD
Institutional Trading of Lucid Diagnostics
Large investors have recently made changes to their positions in the stock. Perkins Capital Management Inc. bought a new stake in shares of Lucid Diagnostics during the 3rd quarter worth about $1,138,000. Ghisallo Capital Management LLC bought a new stake in shares of Lucid Diagnostics during the 3rd quarter worth about $2,990,000. Aberdeen Group plc bought a new stake in shares of Lucid Diagnostics during the 3rd quarter worth about $2,525,000. Deutsche Bank AG bought a new stake in shares of Lucid Diagnostics during the 4th quarter worth about $88,000. Finally, Invesco Ltd. bought a new stake in shares of Lucid Diagnostics during the 2nd quarter worth about $41,000. Institutional investors own 74.01% of the company’s stock.
About Lucid Diagnostics
Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.
Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.
Featured Articles
- Five stocks we like better than Lucid Diagnostics
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
